ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES

Japanese Patent JP2016033150

A

PROBLEM TO BE SOLVED: To provide anti-human IL-21 monoclonal antibodies that inhibit symptoms and biological activities that are expressed as autoimmune disorders and inflammatory disorders and associated with interleukin (IL-21)/IL-21 receptor interaction, as well as methods for using them.SOLUTION: Human anti-human IL-21 monoclonal antibodies and hybridomas producing them are presented. Certain of these antibodies are capable of binding to native human IL-21 protein, recombinant mutant IL-21 proteins, and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, in particular, diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.SELECTED DRAWING: Figure 3

WO/2021/155634	ANTI-HUMAN-TSLP ANTIBODY AND USE THEREOF
WO/2005/019259	VARIANTS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST: COMPOSITIONS AND USES THEREOF
WO/2018/232195	COMPOSITIONS AND METHODS TARGETING COMPLEMENT COMPONENT 3 FOR INHIBITING TUMOR GROWTH

STEPHEN R JASPERS
RIXON MARK W
DILLON STACEY R
RAMSDELL FREDERICK J
CECILE M KREJSA
YI EUGENE C

JP2015230496A

March 10, 2016

November 26, 2015

Click for automatic bibliography generation  

ZYMOGENETICS INC

C07K16/24; A61K39/395; A61P1/00; A61P1/04; A61P1/16; A61P1/18; A61P5/14; A61P7/00; A61P7/06; A61P9/00; A61P9/10; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/04; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P27/02; A61P27/16; A61P29/00; A61P37/02; A61P37/06; A61P43/00; C12N5/12; C12N15/00; C12N15/09

WO2007111714A2	2007-10-04
WO2006057027A1	2006-06-01

Hatsushi Shimizu
Masao Haruna
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Yoshihiro Igarashi
Kazuya Kawamoto

Previous Patent: COMPOSITION FOR MAKEUP COSMETICS, AND MAKEUP COSMETIC

Next Patent: IMMUNOGENIC COMPOSITION AGAINST DENGUE VIRUSES